A Metaxas1, Hl Keyworth, Jh Yoo, Y Chen, I Kitchen, A Bailey. 1. Department of Biochemistry and Physiology, Faculty of Health and Medical Sciences, Institute of Health and Medical Sciences, University of Surrey, Guildford, UK. a.metaxas@vumc.nl
Abstract
BACKGROUND AND PURPOSE: High rates of cigarette smoking occur in cocaine-dependent individuals, reflecting an involvement of nicotinic acetylcholine receptors (nAChRs) in cocaine-elicited behaviour. This study was designed to assess the contribution of different nAChR subtypes to the behavioural and neurochemical effects of chronic cocaine treatment. EXPERIMENTAL APPROACH: Cocaine (15 mg·kg(-1) , i.p.) was administered to male C57BL/6J mice in a chronic 'binge' paradigm, with and without the coadministration of the α7 preferring nAChR antagonist methyllycaconitine (MLA; 5 mg·kg(-1) , i.p.) or the β2* nAChR antagonist dihydro-β-erythroidine (DHβE; 2 mg·kg(-1) , i.p.). Quantitative autoradiography was used to examine the effect of cocaine exposure on α7 and α4β2* nAChRs, and on the high-affinity choline transporter. KEY RESULTS: MLA+cocaine administration induced an intense self-grooming behaviour, indicating a likely role for α7 nAChRs in modulating this anxiogenic, compulsive-like effect of cocaine. In the major island of Calleja, a key area of action for neuroleptics, MLA+cocaine reduced choline transporter binding compared with cocaine (with or without DHβE) administration. DHβE treatment prevented the induction of stereotypy sensitisation to cocaine but prolonged locomotor sensitisation, implicating heteromeric β2* nAChRs in the neuroadaptations mediating cocaine-induced behavioural sensitisation. 'Binge' cocaine treatment region-specifically increased α4β2* nAChR binding in the midbrain dopaminergic regions: ventral tegmental area and substantia nigra pars compacta. CONCLUSIONS AND IMPLICATIONS: We have shown a differential, subtype-selective, contribution of nAChRs to the behavioural and neurochemical sequelae of chronic cocaine administration. These data support the clinical utility of targeting specific nAChR subtypes for the alleviation of cocaine-abuse symptomatology.
BACKGROUND AND PURPOSE: High rates of cigarette smoking occur in cocaine-dependent individuals, reflecting an involvement of nicotinic acetylcholine receptors (nAChRs) in cocaine-elicited behaviour. This study was designed to assess the contribution of different nAChR subtypes to the behavioural and neurochemical effects of chronic cocaine treatment. EXPERIMENTAL APPROACH: Cocaine (15 mg·kg(-1) , i.p.) was administered to male C57BL/6J mice in a chronic 'binge' paradigm, with and without the coadministration of the α7 preferring nAChR antagonist methyllycaconitine (MLA; 5 mg·kg(-1) , i.p.) or the β2* nAChR antagonist dihydro-β-erythroidine (DHβE; 2 mg·kg(-1) , i.p.). Quantitative autoradiography was used to examine the effect of cocaine exposure on α7 and α4β2* nAChRs, and on the high-affinity choline transporter. KEY RESULTS:MLA+cocaine administration induced an intense self-grooming behaviour, indicating a likely role for α7 nAChRs in modulating this anxiogenic, compulsive-like effect of cocaine. In the major island of Calleja, a key area of action for neuroleptics, MLA+cocaine reduced choline transporter binding compared with cocaine (with or without DHβE) administration. DHβE treatment prevented the induction of stereotypy sensitisation to cocaine but prolonged locomotor sensitisation, implicating heteromeric β2* nAChRs in the neuroadaptations mediating cocaine-induced behavioural sensitisation. 'Binge' cocaine treatment region-specifically increased α4β2* nAChR binding in the midbrain dopaminergic regions: ventral tegmental area and substantia nigra pars compacta. CONCLUSIONS AND IMPLICATIONS: We have shown a differential, subtype-selective, contribution of nAChRs to the behavioural and neurochemical sequelae of chronic cocaine administration. These data support the clinical utility of targeting specific nAChR subtypes for the alleviation of cocaine-abuse symptomatology.
Authors: Judith R Homberg; Margot van den Akker; Halfdan S Raasø; George Wardeh; Rob Binnekade; Anton N M Schoffelmeer; Taco J de Vries Journal: Eur J Neurosci Date: 2002-05 Impact factor: 3.386
Authors: Renee D Goodwin; David A Stayner; Matthew J Chinman; Ping Wu; Jacob Kraemer Tebes; Larry Davidson Journal: Compr Psychiatry Date: 2002 Jul-Aug Impact factor: 3.735
Authors: Adrian J Mogg; Paul Whiteaker; J Michael McIntosh; Michael Marks; Allan C Collins; Susan Wonnacott Journal: J Pharmacol Exp Ther Date: 2002-07 Impact factor: 4.030
Authors: Gabe Haller; Manav Kapoor; John Budde; Xiaoling Xuei; Howard Edenberg; John Nurnberger; John Kramer; Andy Brooks; Jay Tischfield; Laura Almasy; Arpana Agrawal; Kathleen Bucholz; John Rice; Nancy Saccone; Laura Bierut; Alison Goate Journal: Hum Mol Genet Date: 2013-09-20 Impact factor: 6.150
Authors: Taline V Khroyan; Dennis Yasuda; Lawrence Toll; Willma E Polgar; Nurulain T Zaveri Journal: Biochem Pharmacol Date: 2015-08-07 Impact factor: 5.858
Authors: Jill R Crittenden; Carolyn J Lacey; Tyrone Lee; Hilary A Bowden; Ann M Graybiel Journal: Front Neural Circuits Date: 2014-05-28 Impact factor: 3.492